BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37528644)

  • 1. p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
    Sakamoto I; Kagami K; Nozaki T; Hirotsu Y; Amemiya K; Oyama T; Omata M
    Am J Surg Pathol; 2023 Oct; 47(10):1144-1150. PubMed ID: 37528644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
    Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
    J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas.
    Matsumoto N; Manrai P; Rottmann D; Wu X; Assem H; Hui P; Buza N
    Int J Gynecol Pathol; 2023 Nov; 42(6):567-575. PubMed ID: 36730675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations.
    Sung YN; Kim D; Kim J
    Diagn Pathol; 2022 Dec; 17(1):92. PubMed ID: 36471402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.
    Vermij L; Léon-Castillo A; Singh N; Powell ME; Edmondson RJ; Genestie C; Khaw P; Pyman J; McLachlin CM; Ghatage P; de Boer SM; Nijman HW; Smit VTHBM; Crosbie EJ; Leary A; Creutzberg CL; Horeweg N; Bosse T;
    Mod Pathol; 2022 Oct; 35(10):1475-1483. PubMed ID: 35752743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized p53 immunohistochemistry is an accurate predictor of
    Köbel M; Piskorz AM; Lee S; Lui S; LePage C; Marass F; Rosenfeld N; Mes Masson AM; Brenton JD
    J Pathol Clin Res; 2016 Oct; 2(4):247-258. PubMed ID: 27840695
    [No Abstract]   [Full Text] [Related]  

  • 7.
    Thiel KW; Devor EJ; Filiaci VL; Mutch D; Moxley K; Alvarez Secord A; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Aghajanian C; Samuelson MI; Lankes HA; Soslow RA; Leslie KK
    J Clin Oncol; 2022 Oct; 40(28):3289-3300. PubMed ID: 35658479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Investigation for pathological interpretation criteria and its prognostic value for P53 expression in Chinese diffuse large B-cell lymphoma].
    Shi YF; Gao ZF; Li XH; Guo LG; Zheng QL; Long MP; Deng LJ; Du TT; Jia L; Zhao W; Song XX; Li M
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1010-1015. PubMed ID: 36709106
    [No Abstract]   [Full Text] [Related]  

  • 9. Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma.
    Kortekaas KE; Solleveld-Westerink N; Tessier-Cloutier B; Rutten TA; Poelgeest MIE; Gilks CB; Hoang LN; Bosse T
    Histopathology; 2020 Jul; 77(1):92-99. PubMed ID: 32236967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pattern-based interpretation of p53 immunohistochemical expression as a surrogate marker for TP53 mutations in colorectal cancer.
    Osakabe M; Yamada N; Sugimoto R; Uesugi N; Nakao E; Honda M; Yanagawa N; Sugai T
    Virchows Arch; 2024 Mar; ():. PubMed ID: 38512505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies.
    Yang G; Anderson Williams S; He F; He Y; McIntyre K; Beckman AK; Nelson AC; Yohe SL
    Pathology; 2024 Apr; 56(3):404-412. PubMed ID: 38341302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
    Köbel M; Kang EY
    Int J Gynecol Pathol; 2021 Jan; 40(1):32-40. PubMed ID: 33290354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoplasmic Pattern p53 Immunoexpression in Pelvic and Endometrial Carcinomas With TP53 Mutation Involving Nuclear Localization Domains: An Uncommon But Potential Diagnostic Pitfall With Clinical Implications.
    Rabban JT; Garg K; Ladwig NR; Zaloudek CJ; Devine WP
    Am J Surg Pathol; 2021 Nov; 45(11):1441-1451. PubMed ID: 33899789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
    Whelan K; Dillon M; Strickland KC; Pothuri B; Bae-Jump V; Borden LE; Thaker PH; Haight P; Arend RC; Ko E; Jackson AL; Corr BR; Ayoola-Adeola M; Wright JD; Podwika S; Smitherman C; Thomas S; Lightfoot M; Newton M; Washington C; Mullen M; Cosgrove C; Harsono AAH; Powell K; Herzog TJ; Salani R; Alvarez Secord A
    Gynecol Oncol; 2023 Nov; 178():44-53. PubMed ID: 37748270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
    Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
    Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refined criteria for p53 expression in ovarian mucinous tumours are highly concordant with TP53 mutation status, but p53 expression/TP53 status lack prognostic significance.
    Dundr P; Hájková N; Kendall Bártů M; Cibula D; Drozenová J; Fabian P; Fadare O; Frühauf F; Hausnerová J; Hojný J; Laco J; Lax SF; Matěj R; Méhes G; Michálková R; Němejcová K; Singh N; Stolnicu S; Švajdler M; Zima T; McCluggage WG; Stružinská I
    Pathology; 2023 Oct; 55(6):785-791. PubMed ID: 37500307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
    Kommoss FKF; Jamieson A; McAlpine JN; Gilks CB
    Am J Surg Pathol; 2024 Mar; 48(3):373. PubMed ID: 38126250
    [No Abstract]   [Full Text] [Related]  

  • 19. In Response to p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
    Sakamoto I; Kagami K; Nozaki T; Hirotsu Y; Amemiya K; Oyama T; Omata M
    Am J Surg Pathol; 2024 Mar; 48(3):374-375. PubMed ID: 38238975
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer.
    Kim KM; Ahn AR; Park HS; Jang KY; Moon WS; Kang MJ; Ha GW; Lee MR; Chung MJ
    BMC Cancer; 2022 Aug; 22(1):940. PubMed ID: 36045334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.